Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03)

Gnant, Michael; C. Dueck, Amylou; Frantal, Sophie; Martín, Miguel; Burstein, H.J.; Greil, Richard; Fox, Peter; C. Wolff, Antonio; Chan, Arlene; P. Winer, Eric; Pfeiler, Georg; D. Miller, Kathy; Colleoni, Marco; M. Suga, Jennifer; Rubovsky, Gabor; M. Bliss, Judith; A. Mayer, Ingrid; F. Singer, Christian; Nowecki, Zbigniew; Hahn, Olwen; Thomson, Jacqui; Wolmark, Norman; Amillano, Kepa; S. Rugo, Hope; G. Steger, Guenther; Hernando Fernández de Aranguiz, Blanca; C. Haddad, Tufia; Perelló, Antonia; Bellet, Meritxell; Fohler, Hannes; Metzger, Otto; Jallitsch-Halper, Anita; Solomon, Kadine; Schurmans, Céline; P. Theall, K.; R. Lu, Dongrui; Tenner, Kathleen; Fesl, Christian; DeMichele, Angela; L. Mayer, Erica; behalf of the PALLAS groups and investigators, on

doi:10.1200/jco.21.02554

Public

Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03)

Published in Journal of Clinical Oncology • Dec 7, 2021

Authors:

Michael Gnant

Amylou C. Dueck

Sophie Frantal

Abstract

PURPOSE Palbociclib is a cyclin-dependent kinase 4 and 6 inhibitor approved for advanced breast cancer. In the adjuvant setting, the potential value of adding palbociclib to endocrine therapy for hormone receptor–positive breast cancer has not been confirmed. PATIENTS AND METHODS In the prospective,...

Subject

Palbociclib

Medicine

Breast cancer

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!